South Africa has begun dosing the first participants in a pioneering HIV vaccine clinical trial in Cape Town, marking a significant milestone for African-led research into one of the continent’s most pressing health challenges. The first-in-human BRILLIANT 011 trial launched on 4 February 2026 at the Desmond Tutu HIV Foundation site at Groote Schuur Hospital, according to the South African Medical Research Council (SAMRC).
The trial is led by the SAMRC together with the Desmond Tutu HIV Foundation and the Wits Health Consortium. Its central aim is to map immune responses that could guide the development of a vaccine against HIV strains circulating in Southern Africa, a region that carries one of the heaviest burdens of the epidemic.
What the trial is testing
According to the SAMRC, the BRILLIANT 011 trial evaluates experimental vaccine components administered with an adjuvant designed to strengthen the body’s immune response. The study is designed to help researchers understand how the immune system reacts to these components, providing data to inform future stages of vaccine development.
The vaccine candidates and adjuvant under evaluation are:
- BG505 GT1.1, a vaccine component being tested in the trial
- 426c.Mod.Core-C4b, a second vaccine component
- The SMNP adjuvant, administered alongside the components to boost immune responses
Professor Glenda Gray, the SAMRC sponsor representative, said the work places the team “in a pivotal position to map immune responses to guide further development,” according to the SAMRC.
A pan-African partnership
The trial forms part of the broader BRILLIANT Consortium, a pan-African initiative led predominantly by women scientists working across eight African nations, according to the SAMRC. The consortium reflects a growing push to place African researchers and institutions at the centre of efforts to develop solutions for diseases that disproportionately affect the continent.
The South African effort is supported by a range of international partners. According to the SAMRC, these include the International AIDS Vaccine Initiative, the Fred Hutchinson Cancer Center, the Scripps Consortium for HIV/AIDS Vaccine Development and Amsterdam University Medical Centers. The collaboration brings together local expertise and global scientific resources in pursuit of a shared goal.
Why it matters
An effective HIV vaccine has long been regarded as one of the most difficult goals in modern medicine, in part because the virus mutates rapidly and exists in many distinct strains. By focusing on the strains circulating in Southern Africa, the BRILLIANT 011 trial seeks to generate insights directly relevant to the communities most affected.
As a first-in-human study, the trial represents an early but important step in the long process of vaccine development. The immune-response data it produces is intended to guide subsequent research rather than to deliver an immediately available vaccine.
The launch of the trial at Groote Schuur Hospital underscores South Africa’s role as a hub for HIV research and signals a broader shift toward African leadership in tackling the epidemic. For the scientists involved, the start of dosing marks the beginning of a research journey that they hope will contribute to the global effort to end HIV.
Leave a Reply